The anti-TIGIT:mIgG2a antibody showed a tumor growth inhibition (TGI) rate comparable to that of anti-PD-1 with a 92% and 93% TGI observed, respectively, with 10% (1/10) complete responses (CR) in both single agent groups (Figures 1A,B). Here, PDCD1 is linked to neoplasm.